Last reviewed · How we verify
Etomidate Induction
At a glance
| Generic name | Etomidate Induction |
|---|---|
| Sponsor | The University of Texas Health Science Center, Houston |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effects of Different Drugs for Glottic Atomization on Postoperative Sore Throat After Thyroid Surgery (PHASE4)
- Randomized Trial of Sedative Choice for Intubation (PHASE4)
- Comparison of Anesthetic Techniques for Early Recovery After Ankle Arthroscopy (NA)
- Induction Agent Choice With Early Mortality and Prognostic Outcomes in Critically Ill Patients
- Dexmedetomidine and Myocardial Protection (NA)
- Nalbuphine Timing Effects on Hemodynamics and Analgesia in Elderly Patients (PHASE4)
- SEdation Versus General Anesthesia for Endovascular Therapy in Acute Ischemic Stroke (PHASE4)
- Anesthesia Management in Endovascular Therapy for Ischemic Stroke - 2 (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Etomidate Induction CI brief — competitive landscape report
- Etomidate Induction updates RSS · CI watch RSS
- The University of Texas Health Science Center, Houston portfolio CI